On this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis."

RCTS Supporting Approvals: doi.org/10.1136/bmj.l5221

Back us on Patreon! patreon.com/plenarysession

September 2019

2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci

Plenary Session - inactive due to federal service